HIGH

Ascend Laboratories Recalls Alkem Atorvastatin Calcium 20 mg Tablets for Dissolution Failures (3 NDC

Ascend Laboratories recalls Alkem Atorvastatin Calcium Tablets USP 20 mg for dissolution failures in 2025. Distributed by Ascend Laboratories, Parsippany, NJ, nationwide. The issue: dissolution specifications not met. Stop use immediately and follow recall instructions. Check your NDC numbers to identify affected lots.

Quick Facts at a Glance

Recall Date
September 19, 2025
Hazard Level
HIGH
Brands
Ascend Laboratories, Alkem Laboratories
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT

Hazard Information

Failed Dissolution Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Ascend Laboratories, LLC or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Atorvastatin calcium tablets are prescribed to lower cholesterol and reduce cardiovascular risk. The recalled lots were distributed nationwide in the United States.

Why This Is Dangerous

Dissolution failure can lead to inconsistent absorption, potentially reducing efficacy and impacting lipid control.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Patients may experience subtherapeutic dosing which could affect cholesterol management and cardiovascular risk.

Practical Guidance

How to identify if yours is affected

  1. Identify NDC codes on the packaging: 67877-512-90, 67877-512-05, 67877-512-10
  2. Verify packaging lot and expiration to ensure recall applicability
  3. Cross-check with medical provider's prescription information

Where to find product info

NDC codes on the bottle label and packaging; recall notification letters to healthcare facilities

What timeline to expect

Recall notifications may lead to refunds or replacements; processing times vary

If the manufacturer is unresponsive

  • Document all communications with Ascend Laboratories
  • File a consumer complaint with the FDA if there is no timely response
  • Consult a healthcare provider for alternatives during the recall period

How to prevent similar issues

  • Always verify NDC numbers before dispensing or consuming generic medications
  • Purchase from reputable pharmacies or verified distributors
  • Keep recall communications and packaging for reference

Documentation advice

Retain recall notices, packaging, prescription records, and correspondence with the manufacturer

Product Details

Product: Atorvastatin Calcium Tablets USP, 20 mg, Rx Only. 90-count NDC 67877-512-90; 500-count NDC 67877-512-05; 1000-count NDC 67877-512-10. Manufactured by: Alkem Laboratories, Ltd. India. Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054. Sold nationwide in the U.S.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • NDC 67877-512-90
  • NDC 67877-512-05
  • NDC 67877-512-10
  • Distributed nationwide in the U.S.
  • Hazard: Dissolution specification failures
  • Active recall as of 2025-10-22

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
7/ 10
Affected Groups
GENERALPREGNANT
Injury Types
OTHER

Product Details

Model Numbers
NDC 67877-512-90
NDC 67877-512-05
NDC 67877-512-10
UPC Codes
67877-511
67877-512
67877-513
+11 more
Affected States
ALL
Report Date
October 22, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more